{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:01:01Z","timestamp":1783771261478,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009991","name":"Jilin Province Department of Finance","doi-asserted-by":"publisher","award":["JLSWSRCZX2021-056"],"award-info":[{"award-number":["JLSWSRCZX2021-056"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jpba.2025.116846","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:05:26Z","timestamp":1743397526000},"page":"116846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Simultaneous quantification of methotrexate, 7-hydroxymethotrexate and creatinine in serum by LC-MS\/MS for predicting delayed elimination"],"prefix":"10.1016","volume":"261","author":[{"given":"Yingying","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunzi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengchao","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8829","authenticated-orcid":false,"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116846_bib1","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1007\/s11033-020-05481-9","article-title":"Molecular mechanism of action and pharmacokinetic properties of methotrexate","volume":"47","author":"Maksimovic","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.jpba.2025.116846_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/17425247.2012.642362","article-title":"Methotrexate: a detailed review on drug delivery and clinical aspects","volume":"9","author":"Khan","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jpba.2025.116846_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jpba.2025.116846_bib4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jpha.2019.06.001","article-title":"Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples","volume":"9","author":"Karami","year":"2019","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2025.116846_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00296-020-04547-y","article-title":"Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction","volume":"40","author":"Lee","year":"2020","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.jpba.2025.116846_bib6","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.29518","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","author":"Hamed","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jpba.2025.116846_bib7","first-page":"1273","article-title":"Evaluation of an oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization","volume":"30","author":"Heisler","year":"2022","journal-title":"Support. Care Cancer: Off. J. Multinatl. Assoc. Support. Care Cancer"},{"key":"10.1016\/j.jpba.2025.116846_bib8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/phar.1935","article-title":"Outcomes associated with reducing the urine alkalinization threshold in patients receiving high-dose methotrexate","volume":"37","author":"Drost","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpba.2025.116846_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/abbs\/gmz137","article-title":"Antidotal effects of calcium folinate against high-dose methotrexate-induced damages to mouse matured oocytes","volume":"52","author":"Tian","year":"2020","journal-title":"Acta Biochim. Et. Biophys. Sin."},{"key":"10.1016\/j.jpba.2025.116846_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2025.125801","article-title":"Sers-based methodology for nanomolar methotrexate concentration detection for clinics","author":"Demishkevich","year":"2025","journal-title":"Spectrochim. Acta Part A: Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.jpba.2025.116846_bib11","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jpba.2025.116846_bib12","article-title":"Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients","volume":"13","author":"Mosleh","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jpba.2025.116846_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00432-024-05945-6","article-title":"A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment","volume":"150","author":"Bielack","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jpba.2025.116846_bib14","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1111\/bcp.15134","article-title":"Medication therapy of high-dose methotrexate: an evidence-based practice guideline of the Division of Therapeutic Drug Monitoring","volume":"88","author":"Song","year":"2022","journal-title":"Chin. Pharmacol. Soc., Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116846_bib15","first-page":"599","article-title":"The influence of 7-OH methotrexate metabolite on clinical relevance of methotrexate determination","volume":"57","author":"Klapkova","year":"2011","journal-title":"Clin. Lab."},{"key":"10.1016\/j.jpba.2025.116846_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FTD.0000000000000445","article-title":"Plasma 7-hydroxymethotrexate levels versus methotrexate to predict delayed elimination in children receiving high-dose methotrexate","volume":"40","author":"Fabresse","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2025.116846_bib17","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/CAD.0b013e32835b8662","article-title":"Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia","volume":"24","author":"Csordas","year":"2013","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.jpba.2025.116846_bib18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/028418698429586","article-title":"Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia: a logistic regression analysis","volume":"37","author":"Rask","year":"2009","journal-title":"Acta Oncol."},{"key":"10.1016\/j.jpba.2025.116846_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27637","article-title":"Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: a Danish population-based study","volume":"66","author":"Schmidt","year":"2019","journal-title":"Pediatr. blood Cancer"},{"key":"10.1016\/j.jpba.2025.116846_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-013-2319-2","article-title":"Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies","volume":"73","author":"Xu","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116846_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00280-002-0552-1","article-title":"High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL)","volume":"51","author":"Sk\u00e4rby","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116846_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4149\/neo_2014_011","article-title":"Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies","volume":"61","author":"Mao","year":"2014","journal-title":"Neoplasma"},{"key":"10.1016\/j.jpba.2025.116846_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143205","article-title":"A risk assessment of the Jaffe vs enzymatic method for creatinine measurement in an outpatient population","volume":"10","author":"Schmidt","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jpba.2025.116846_bib24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ansa.202000074","article-title":"Trend in creatinine determining methods: conventional methods to molecular-based methods","volume":"2","author":"Narimani","year":"2020","journal-title":"Anal. Sci. Adv."},{"key":"10.1016\/j.jpba.2025.116846_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1373\/clinchem.2011.172288","article-title":"Specificity characteristics of 7 commercial creatinine measurement procedures by enzymatic and Jaffe method principles","volume":"58","author":"Greenberg","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2025.116846_bib26","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.cca.2010.07.013","article-title":"An automated turbulent flow liquid chromatography-isotope dilution mass spectrometry (LC-IDMS) method for quantitation of serum creatinine","volume":"411","author":"Harlan","year":"2010","journal-title":"Clin. Chim. Acta; Int. J. Clin. Chem."},{"key":"10.1016\/j.jpba.2025.116846_bib27","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.clinbiochem.2010.05.018","article-title":"Development and validation of a rapid liquid chromatography isotope dilution tandem mass spectrometry (LC-IDMS\/MS) method for serum creatinine","volume":"43","author":"H\u00e9tu","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2025.116846_bib28","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jchromb.2018.07.005","article-title":"Bioanalytical method validation of endogenous substances according to guidelines by the FDA and other organizations: basic need to specify concentration ranges","volume":"1093-1094","author":"Tsikas","year":"2018","journal-title":"J. Chromatogr. B, Anal. Technol. Biomed. life Sci."},{"key":"10.1016\/j.jpba.2025.116846_bib29","first-page":"1536532","article-title":"Simultaneous quantification of methotrexate and its metabolite 7-hydroxy-methotrexate in human plasma for therapeutic drug monitoring","author":"Ren","year":"2019","journal-title":"Int J. Anal. Chem. 2019"},{"key":"10.1016\/j.jpba.2025.116846_bib30","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00257517","article-title":"Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy","volume":"15","author":"Erttmann","year":"1985","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2025.116846_bib31","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1172\/JCI108308","article-title":"7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate","volume":"57","author":"Jacobs","year":"1976","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jpba.2025.116846_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1515\/tjb-2019-0357","article-title":"Measurement of serum creatinine levels with liquid chromatography-tandem mass spectrometry: comparison with Jaffe and enzymatic methods","volume":"46","author":"Yildirimel","year":"2021","journal-title":"Turk. J. Biochem."},{"key":"10.1016\/j.jpba.2025.116846_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1258\/000456306776021544","article-title":"Validation of a liquid chromatography tandem mass spectrometry assay for serum creatinine and comparison with enzymatic and Jaffe methods","volume":"43","author":"Owen","year":"2006","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.jpba.2025.116846_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clinms.2018.11.004","article-title":"A simplified, rapid LC-MS\/MS assay for serum and salivary creatinine","volume":"11","author":"Bernstone","year":"2019","journal-title":"Clin. Mass Spectrom."},{"key":"10.1016\/j.jpba.2025.116846_bib35","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3109\/08880018.2015.1087612","article-title":"Serum creatinine versus plasma methotrexate levels to predict toxicities in children receiving high-dose methotrexate","volume":"32","author":"Tiwari","year":"2015","journal-title":"Pediatr. Hematol. Oncol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525001876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525001876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:01:08Z","timestamp":1778752868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525001876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":35,"alternative-id":["S0731708525001876"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116846","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous quantification of methotrexate, 7-hydroxymethotrexate and creatinine in serum by LC-MS\/MS for predicting delayed elimination","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116846","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116846"}}